Vertex Pharmaceuticals Inc. (VRTX): Price and Financial Metrics


Vertex Pharmaceuticals Inc. (VRTX): $302.02

1.38 (+0.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VRTX POWR Grades

  • Quality is the dimension where VRTX ranks best; there it ranks ahead of 98.69% of US stocks.
  • VRTX's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • VRTX ranks lowest in Momentum; there it ranks in the 25th percentile.

VRTX Stock Summary

  • With a market capitalization of $74,255,278,418, VERTEX PHARMACEUTICALS INC has a greater market value than 97.58% of US stocks.
  • Of note is the ratio of VERTEX PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 11.47% of US stocks have a lower such ratio.
  • VRTX's price/sales ratio is 8.89; that's higher than the P/S ratio of 87.48% of US stocks.
  • If you're looking for stocks that are quantitatively similar to VERTEX PHARMACEUTICALS INC, a group of peers worth examining would be MU, AMAT, INTC, LRCX, and REGN.
  • Visit VRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.vrtx.com.

VRTX Valuation Summary

  • VRTX's price/sales ratio is 8.7; this is 357.89% higher than that of the median Healthcare stock.
  • Over the past 243 months, VRTX's price/earnings ratio has gone up 38.7.

Below are key valuation metrics over time for VRTX.

Stock Date P/S P/B P/E EV/EBIT
VRTX 2022-09-23 8.7 6.1 22.8 16.2
VRTX 2022-09-22 8.8 6.2 23.0 16.4
VRTX 2022-09-21 8.6 6.0 22.5 16.0
VRTX 2022-09-20 8.8 6.2 23.0 16.5
VRTX 2022-09-19 8.8 6.1 22.9 16.3
VRTX 2022-09-16 8.9 6.2 23.3 16.6

VRTX Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at 13.72%.
  • Its 4 year revenue growth rate is now at 190.09%.
  • Its year over year net income to common stockholders growth rate is now at -11.26%.
Over the past 52 months, VRTX's revenue has gone up $5,935,692,000.

The table below shows VRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 8,350.425 4,018.212 3,194.638
2022-03-31 7,947.595 2,678.645 2,451.062
2021-12-31 7,574.4 2,643.5 2,342.1
2021-09-30 7,129.659 2,140.039 2,176.18
2021-06-30 6,683.766 2,120.568 1,991.686
2021-03-31 6,414.881 3,358.862 2,762.032

VRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRTX has a Quality Grade of B, ranking ahead of 86.88% of graded US stocks.
  • VRTX's asset turnover comes in at 0.564 -- ranking 66th of 681 Pharmaceutical Products stocks.
  • ORGO, MDWD, and CCXI are the stocks whose asset turnover ratios are most correlated with VRTX.

The table below shows VRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.564 0.879 0.725
2021-03-31 0.565 0.881 1.066
2020-12-31 0.589 0.881 1.053
2020-09-30 0.619 0.880 1.013
2020-06-30 0.618 0.877 0.796
2020-03-31 0.607 0.872 0.605

VRTX Price Target

For more insight on analysts targets of VRTX, see our VRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $258.59 Average Broker Recommendation 1.54 (Moderate Buy)

VRTX Stock Price Chart Interactive Chart >

Price chart for VRTX

VRTX Price/Volume Stats

Current price $302.02 52-week high $305.95
Prev. close $300.64 52-week low $176.36
Day low $296.80 Volume 1,296,600
Day high $304.26 Avg. volume 1,617,018
50-day MA $288.20 Dividend yield N/A
200-day MA $263.06 Market Cap 77.46B

Vertex Pharmaceuticals Inc. (VRTX) Company Bio


Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, near Oxford, England. (Source:Wikipedia)


VRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

VRTX Latest Social Stream


Loading social stream, please wait...

View Full VRTX Social Stream

Latest VRTX News From Around the Web

Below are the latest news stories about VERTEX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

3 Growth Stocks Poised to Skyrocket

What's better than a growth stock that's performed well in the past? The answer is easy: A growth stock that should perform well in the future. Here's why they chose Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Yahoo | October 1, 2022

Vertex Stock Flashes Buy Signal; Gene-Editing Play Leads 5 Resilient Stocks In Bear Market

Vertex Pharmaceuicals flashed a buy signal last week on positive gene-editing news. It's one of several resilient stocks to watch in the bear market.

Yahoo | October 1, 2022

VRTX vs. SRPT: Which Biotech Stock is Better?

hate relationship with the biotechnology sector, and it's easy to see why they are split on the sector. In this piece, we used TipRanks' Comparison Tool to evaluate two biotech stocks. Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT) are two of the biggest players in biotech, but the two couldn't be more different. While VRTX is a steady, profitable company, SRPT is riskier but may offer a better opportunity. Taking the Plunge into Biotech Biotechnology has become a critical part of the healthcare sector. It's important to understand the difference between biotech and pharmaceuticals.

Michelle Jones on TipRanks | September 30, 2022

Dow Jones Drops On Hot Inflation Data; Tesla Stock Rises Before AI Day

The Dow Jones Industrial Average dropped Friday on hot inflation data. Tesla stock fell ahead of the company's AI Day.

Yahoo | September 30, 2022

Got $1,000? 2 Safe Stocks to Buy This Month

If you're not familiar with Vertex Pharmaceuticals (NASDAQ: VRTX), this healthcare stock is certainly one to put on your radar. The company develops and manufactures medicines that treat rare diseases. As of right now, it has four approved products, and all of them treat cystic fibrosis.

Yahoo | September 30, 2022

Read More 'VRTX' Stories Here

VRTX Price Returns

1-mo 8.18%
3-mo 2.63%
6-mo 7.76%
1-year 66.94%
3-year 75.54%
5-year 94.73%
YTD 37.53%
2021 -7.08%
2020 7.94%
2019 32.13%
2018 10.58%
2017 103.42%

Continue Researching VRTX

Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:

Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5481 seconds.